Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,276
archived clinical trials in
Pancreatic Cancer

Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
1444
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute
953
mi
from
Huntersville, NC
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute
953
mi
from
Huntersville, NC
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
1223
mi
from
Philadelphia, PA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
1223
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
618
mi
from
Nashville, TN
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
1344
mi
from
New Haven, CT
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
663
mi
from
Louisville, KY
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
663
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland
1148
mi
from
Baltimore, MD
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Neely Center for Clinical Cancer Research, Tufts Medical Center
1444
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Neely Center for Clinical Cancer Research, Tufts Medical Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Advanced Lung and Non-colorectal Gastrointestinal Malignancies
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
Randomized Study of Early Palliative Care Integrated With Standard Oncology Care Versus Standard Oncology Care Alone in Patients With Advanced Lung and Non-colorectal Gastrointestinal Malignancies
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
National Cancer Institute
1123
mi
from
Bethesda, MD
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
National Cancer Institute
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Herbert Irving Comprehensive Cancer Center of Columbia University
1286
mi
from
New York, NY
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Herbert Irving Comprehensive Cancer Center of Columbia University
1286
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
1052
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Providence Portland Medical Center
1383
mi
from
Portland, OR
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Providence Portland Medical Center
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Medical Center
1410
mi
from
Seattle, WA
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Medical Center
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center
1112
mi
from
Tampa, FL
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
NYU Langone Medical Center
1288
mi
from
New York, NY
Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer
A Phase 2, Randomized, Multicenter, Open-Label Study of the Efficacy and Immune Response of the Sequential Administration of GVAX Pancreas Vaccine Alone or Followed by CRS-207 in Adults With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
NYU Langone Medical Center
1288
mi
from
New York, NY
Click here to add this to my saved trials
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib)
Status: Enrolling
Updated:  12/31/1969
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Treatment of Advanced Colorectal or Pancreatic Cancer With Anti-CD3 x Anti-EGFR-Armed Activated T-Cells (Phase Ib)
Status: Enrolling
Updated: 12/31/1969
Barbara Ann Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1149
mi
from
Baltimore, MD
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Phase II Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin in Subjects With Metastatic Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  12/31/1969
University of Florida Shands Cancer Center
1049
mi
from
Gainesville, FL
Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
GAIN-1 Study: Gemcitabine With Abraxane and Other Investigational Therapies in Neoadjuvant Treatment of Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 12/31/1969
University of Florida Shands Cancer Center
1049
mi
from
Gainesville, FL
Click here to add this to my saved trials
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer
A Phase 1b Clinical Trial of LDE225 in Combination With Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan (FOLFIRINOX) in Previously Untreated Locally Advanced or Metastatic Pancreatic Adenocarcinoma, With an Expansion Cohort at the Recommended Phase 2 Dose
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton or Photon RT Plus Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Short Course Radiation Therapy With Proton or Photon Beam Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Phase II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Proton or Photon RT Plus Capecitabine and Hydroxychloroquine for Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1127
mi
from
Washington,
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1127
mi
from
Washington,
Click here to add this to my saved trials
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
349
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
541
mi
from
The Woodlands, TX
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
541
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
398
mi
from
Tyler, TX
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
398
mi
from
Tyler, TX
Click here to add this to my saved trials
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1317
mi
from
Wenatchee, WA
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1317
mi
from
Wenatchee, WA
Click here to add this to my saved trials
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated:  12/31/1969
1214
mi
from
Calgary,
A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer
A Randomized Phase 2 Placebo-Controlled Study of LY2495655 in Patients With Advanced or Metastatic Pancreatic Cancer Receiving Chemotherapy
Status: Enrolling
Updated: 12/31/1969
1214
mi
from
Calgary,
Click here to add this to my saved trials
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas
A Phase II Study of Preoperative Systemic Chemotherapy (Modified FOLFIRINOX) Followed by Radiation Therapy for Patients With High Risk Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
572
mi
from
Houston, TX
Click here to add this to my saved trials
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
1123
mi
from
Bethesda, MD
Click here to add this to my saved trials
FOLFIRINOX + RT for Pancreatic Cancer
Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
FOLFIRINOX + RT for Pancreatic Cancer
Phase II Study of Preoperative FOLFIRINOX Followed by Accelerated Short Course Radiation Therapy for Borderline-Resectable Pancreatic Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
Status: Enrolling
Updated:  12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1149
mi
from
Baltimore, MD
Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
Pilot Study Evaluating An Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine (GVAX) and Low Dose Cyclophosphamide Integrated With Fractionated Stereotactic Body Radiation Therapy (SBRT) and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas
Status: Enrolling
Updated: 12/31/1969
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1149
mi
from
Baltimore, MD
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
1344
mi
from
New Haven, CT
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Helen F. Graham Cancer Center
1195
mi
from
Newark, DE
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Helen F. Graham Cancer Center
1195
mi
from
Newark, DE
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
MD Anderson Cancer Center Orlando (UF Health Cancer Center)
1141
mi
from
Orlando, FL
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
MD Anderson Cancer Center Orlando (UF Health Cancer Center)
1141
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
IU Health Goshen Cancer Center
689
mi
from
Goshen, IN
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
IU Health Goshen Cancer Center
689
mi
from
Goshen, IN
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Massachusettes General Hospital
1444
mi
from
Boston, MA
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Massachusettes General Hospital
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Weill Cornell -New York Presbyterian Hospital
1225
mi
from
New York, NY
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Weill Cornell -New York Presbyterian Hospital
1225
mi
from
New York, NY
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
1290
mi
from
New York, NY
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
1290
mi
from
New York, NY
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Vanderbilt-Ingram Cancer Center
618
mi
from
Nashville, TN
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Vanderbilt-Ingram Cancer Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Texas Oncology Sammons Cancer Center
347
mi
from
Dallas, TX
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Texas Oncology Sammons Cancer Center
347
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Virginia Mason Cancer Center
1410
mi
from
Seattle, WA
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Virginia Mason Cancer Center
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
1112
mi
from
Tampa, FL
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
1112
mi
from
Tampa, FL
Click here to add this to my saved trials
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated:  12/31/1969
University of Colorado Anschutz Medical Campus
402
mi
from
Aurora, CO
Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers
A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients With Epithelial Cancers
Status: Enrolling
Updated: 12/31/1969
University of Colorado Anschutz Medical Campus
402
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
1061
mi
from
Jacksonville, FL
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
1061
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer
Phase I/II Study of LY2090314 and Chemotherapy in Metastatic Pancreatic Cancer Patients With Metastases Amenable to Biopsy
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials